ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Royalty Pharma plc (RPRX) stock surged +1.20%, trading at $32.85 on NASDAQ, up from the previous close of $32.46. The stock opened at $32.24, fluctuating between $32.00 and $32.91 in the recent session.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Employees | 75 |
Beta | 0.47 |
Sales or Revenue | $2.35B |
5Y Sales Change% | 0.038% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |